• LAST PRICE
    5.7000
  • TODAY'S CHANGE (%)
    Trending Up0.3303 (6.1512%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    5.4000 / 5.3697
  • Day Range
    Low 5.3900
    High 5.7500
  • 52 Week Range
    Low 5.3500
    High 18.4950
  • Volume
    92,258
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 5.3697
TimeVolumeACOG
09:32 ET7865.4
09:37 ET1005.4
09:42 ET57875.4
09:46 ET96005.4499
09:48 ET6005.46
09:51 ET3505.475
09:53 ET40005.5
10:18 ET6005.7
10:22 ET145805.7
10:24 ET3505.6
11:09 ET10005.72
11:27 ET91005.705
12:06 ET3605.6999
12:39 ET1005.6449
01:44 ET66005.5
01:45 ET13335.6
01:47 ET2005.64
01:51 ET4005.67
02:07 ET6005.5
02:12 ET70845.5
02:27 ET2005.57
02:32 ET3525.6535
02:57 ET1005.64
03:06 ET3405.6337
03:12 ET101325.65
03:14 ET45895.65
03:15 ET18125.65
03:19 ET2005.67
03:21 ET1005.66
03:24 ET28745.65
03:26 ET6005.65
03:37 ET5005.7
03:44 ET5005.7
03:53 ET3005.7
04:00 ET11105.7
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesACOG
Alpha Cognition Inc
48.9M
0.0x
---
As of 2024-11-19

Company Information

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

Contact Information

Headquarters
c/o 1200 - 750 West Pender StreetVancouver, BC, Canada V6C 2T8
Phone
604-564-9244
Fax
---

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$48.9M
Revenue (TTM)
$0.00
Shares Outstanding
6.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
3.08
EPS
$-4.76
Book Value
$-1.40
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.